Company Description

Genexgen is a precision epigenetic therapeutics company developing programmable medicines to rebalance immune hyperactivity at its root cause. Its lead program, UniGex-01, is an mRNA-encoded zinc-finger repressor delivered via proprietary lipid nanoparticles, designed to selectively down-regulate MYD88 — a master regulator of innate immune signaling. Rather than broadly suppressing the immune system, Genexgen’s approach fine-tunes transcriptional control to restore immune equilibrium.